Shield Therapeutics (@ShieldTx) header
Shield Therapeutics (@ShieldTx) profile picture

Shield Therapeutics

@ShieldTx

Shield is a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs.

 London, England
shieldtx.com
Joined February 2012
  • Tweets775
  • Following133
  • Followers619
139Media
Photo by Shield Therapeutics (@ShieldTx)Photo by Shield Therapeutics (@ShieldTx)Photo by Shield Therapeutics (@ShieldTx)Photo by Shield Therapeutics (@ShieldTx)Photo by Shield Therapeutics (@ShieldTx)Photo by Shield Therapeutics (@ShieldTx)Photo by Shield Therapeutics (@ShieldTx)Photo by Shield Therapeutics (@ShieldTx)Photo by Shield Therapeutics (@ShieldTx)Photo by Shield Therapeutics (@ShieldTx)
Shield Therapeutics retweeted
Proactive (@proactive_x) profile picture
Proactive
@proactive_x23 Jul 2025
Shield Therapeutics shares surge 21% as ACCRUFeR revenues double @ShieldTx #AIM #OTCQB #STX #SHIEF ow.ly/wt9X106gFc3
Shield Therapeutics shares surge 21% as ACCRUFeR revenues double

Shield Therapeutics shares surge 21% as ACCRUFeR revenues double

Markets and small-cap news.

themarketreporter.co.uk
4
5
612
Shield Therapeutics retweeted
Craig Ribton (@Craig_Ribton) profile picture
Craig Ribton
@Craig_Ribton23 Jul 2025
$STX Shield Therapeutics shares surge 21% as ACCRUFeR revenues double tinyurl.com/2cvhs366 @ShieldTx $SHIEF #STX #SHIEF
Shield Therapeutics shares surge 21% as ACCRUFeR revenues double

Shield Therapeutics shares surge 21% as ACCRUFeR revenues double

Markets and small-cap news.

themarketreporter.co.uk
3
3
226
Shield Therapeutics retweeted
Hardman & Co (@HardmanandCo) profile picture
Hardman & Co@HardmanandCo23 Jul 2025
$STX Positive 2Q'25 update from @ShieldTx with US #Accrufer Rx above forecast at 47k (45k est), up 28% over 1Q'25, and at a better average price $231 ($225 est). Cash position also stronger at $10.8m. Augurs well to reach cashflow breakeven by year-end. shieldtherapeutics.com/inves…
3
1
4
1,316
Shield Therapeutics retweeted
Walbrook PR (@WalbrookPR) profile picture
Walbrook PR@WalbrookPR11 Mar 2025
.@ShieldTx (AIM: #STX) launches ACCRUFeR® in Canada 👉Launched with partner Kye Pharmaceuticals 💰milestone payments and double-digit royalties on net sales of ACCRUFeR® 🌎Expanding global footprint 🔗londonstockexchange.com/news…

ACCRUFeR® launched in Canada - (STX) | London Stock Exchange

RNS News Article Page - LSET

londonstockexchange.com
2
4
195
Shield Therapeutics retweeted
Proactive (@proactive_x) profile picture
Proactive
@proactive_x29 Oct 2024
$STX Shield Therapeutics on track after strong quarter as it looks to raise $10m in new investment tinyurl.com/2bgof5tg @ShieldTx $SHIEF #STX #SHIEF
3
2
665
Shield Therapeutics retweeted
Proactive (@proactive_x) profile picture
Proactive
@proactive_x29 Oct 2024
$STX Shield Therapeutics Eyes Cash Flow Positive Target by 2025 tinyurl.com/2ayz8mpw @ShieldTx $SHIEF #STX #SHIEF
4
2
772
Shield Therapeutics retweeted
Vox Markets (@VOXmarkets) profile picture
Vox Markets
@VOXmarkets11 May 2024
Shield Therapeutics triples revenues in FY23, advances global expansion efforts #AIM #STX @ShieldTx #pharma #irondeficiency #anaemia Read the View from Vox here: voxmarkets.co.uk/articles/sh… #investing #shares #voxmarkets via @VOXmarkets

Shield Therapeutics triples revenues in FY23, advances global expansion efforts

Shield Therapeutics reports 2.8x revenue growth in FY23, driven by increasing adoption of Accrufer in the US. The company also highlights significant operational progress, including a paediatric...

voxmarkets.com
5
5
1,003
Shield Therapeutics retweeted
Walbrook PR (@WalbrookPR) profile picture
Walbrook PR@WalbrookPR21 Feb 2024
📢@ShieldTx announces topline results for Q4 2023 & provides an unaudited trading update for FY23 #STX 💰Total rev & other income of $17.5m 💵Accrufer rev of $11.6m approx. 3.1x increase over FY22 📑21%⬆️in H2 Accrufer average net selling 🔗shorturl.at/fpGJ5
Image from Walbrook PR (@WalbrookPR)
2
2
3
1,639
Shield Therapeutics retweeted
Vox Markets (@VOXmarkets) profile picture
Vox Markets
@VOXmarkets21 Feb 2024
Shield Therapeutics - Unaudited Full Year Trading Update @ShieldTx #STX #LSE #pharma Read the RNS here: voxmarkets.co.uk/rns/announc…
Shield Therapeutics Plc (STX.L) | Stock Information | Vox Markets

Shield Therapeutics Plc (STX.L) | Stock Information | Vox Markets

Shield Therapeutics is a commercial stage specialty pharmaceutical company. Delivering innovative speciality pharmaceuticals to address significant unmet needs...

voxmarkets.com
2
1
2
4,817
Shield Therapeutics retweeted
Edison (@Edison_Inv_Res) profile picture
Edison@Edison_Inv_Res11 Jan 2024
Shield Therapeutics — New CFO to support US traction. $STX #AIM @ShieldTx ow.ly/Hakl50QpPJU

Shield Therapeutics — New CFO to support US traction

Shield Therapeutics has appointed Santosh Shanbhag as chief financial officer (CFO) and member of the executive leadership team.

edisongroup.com
1
1
3
2,037
Shield Therapeutics retweeted
Ruth Gemmell (@ruth_proactive) profile picture
Ruth Gemmell@ruth_proactive7 Dec 2023
$STX Shield Therapeutics PLC takes bold approach in the US tinyurl.com/ynlxf3t6 @shieldTx $SHIEF #STX #SHIEF
1
4
601
Shield Therapeutics retweeted
Vox Markets (@VOXmarkets) profile picture
Vox Markets
@VOXmarkets7 Dec 2023
Shield Therapeutics - Q3 2023 U.S. Commercial Highlights @ShieldTx #STX #AIM #pharma Read more here: hubs.ly/Q02cjsj40
Shield Therapeutics Plc (STX.L) | Stock Information | Vox Markets

Shield Therapeutics Plc (STX.L) | Stock Information | Vox Markets

Shield Therapeutics is a commercial stage specialty pharmaceutical company. Delivering innovative speciality pharmaceuticals to address significant unmet needs...

voxmarkets.com
2
3
741
Shield Therapeutics retweeted
Proactive (@proactive_x) profile picture
Proactive
@proactive_x7 Dec 2023
$STX Shield makes significant commercial traction with prescriptions up 76% tinyurl.com/2x4o99rn @shieldTx $SHIEF #STX #SHIEF
Shield makes significant commercial traction with prescriptions up 76%

Shield makes significant commercial traction with prescriptions up 76%

Markets and small-cap news.

themarketreporter.co.uk
1
3
660
Shield Therapeutics retweeted
Walbrook PR (@WalbrookPR) profile picture
Walbrook PR@WalbrookPR7 Dec 2023
Shield Therapeutics (AIM: #STX, @ShieldTx) Q3 highlights 📈Increase in average net selling price of 24% to $148/perscription 💰Net revenue of $4.1m 📈Perscriptions up 76% sequentially, exceeding 54k for the first nine months of 2023 🔗londonstockexchange.com/news…

Q3 2023 U.S. Commercial Highlights - (STX) | London Stock Exchange

RNS News Article Page - LSET

londonstockexchange.com
1
1
261
Shield Therapeutics retweeted
Vox Markets (@VOXmarkets) profile picture
Vox Markets
@VOXmarkets7 Dec 2023
Shield Therapeutics' Accrufer sees 76% surge in prescriptions at 24% higher price in Q3 @ShieldTx #STX #AIM #pharma Read more news: hubs.ly/Q02cj-7c0

Shield Therapeutics' Accrufer sees 76% surge in prescriptions at 24% higher price in Q3

Shield Therapeutics celebrates a strong Q3 as its flagship Accrufer treatment for iron deficiency achieves a 76% surge in prescriptions and a 24% increase in average net selling price in the US....

voxmarkets.com
3
5
670
Shield Therapeutics retweeted
Walbrook PR (@WalbrookPR) profile picture
Walbrook PR@WalbrookPR12 Oct 2023
Shield Therapeutics (AIM: #STX, @ShieldTx) CFO transition 👤Hans-Peter Rudolf is standing down from his role as CFO ↪️Group Company Controller/CEO covering in the interim as search starts 🔗londonstockexchange.com/news…

Chief Financial Officer Transition - (STX) | London Stock Exchange

RNS News Article Page - LSET

londonstockexchange.com
1
1
439
Shield Therapeutics retweeted
Proactive (@proactive_x) profile picture
Proactive
@proactive_x3 Oct 2023
$STX Shield Therapeutics: A case of cautious optimism amid revised guidance tinyurl.com/yoh5abny @shieldTx $SHIEF #STX #SHIEF
1
1
2
2,100
Shield Therapeutics retweeted
Walbrook PR (@WalbrookPR) profile picture
Walbrook PR@WalbrookPR29 Sep 2023
📈@ShieldTx (AIM: #STX) is tipped in the Tempus column today in @thetimes with a BUY recommendation 🗣️ADVICE Buy 🗣️WHY Speculative, but the odds are turning in Shield’s favour thetimes.co.uk/article/tempu…

Tempus: Shipbuilder Babcock International sails out of choppy waters

There was an understandable rush for shares in Babcock International, along with other defence contractors, when Russia invaded Ukraine last year. But then they

thetimes.com
1
3
395
Shield Therapeutics retweeted
Walbrook PR (@WalbrookPR) profile picture
Walbrook PR@WalbrookPR29 Sep 2023
📰@ShieldTx (AIM: #STX) hails progress in Stateside venture as losses narrow business-live.co.uk/manufact…

Shield Therapeutics hails progress in Stateside venture as losses narrow

The firm has secured additional funding to speed up its entry to the US market

business-live.co.uk
1
1
250
Shield Therapeutics retweeted
Walbrook PR (@WalbrookPR) profile picture
Walbrook PR@WalbrookPR29 Sep 2023
Shield Therapeutics’ iron deficiency treatment prescriptions continue to surge, plans to raise $27.4m for further expansion @ShieldTx voxmarkets.co.uk/articles/sh… #investing #shares #voxmarkets via @VOXmarkets

Shield Therapeutics’ iron deficiency treatment prescriptions continue to surge, plans to raise...

Shield Therapeutics reported a 65% revenue increase in H1 driven by strong Accrufer® prescription growth, targeting 100,000 to 130,000 total prescriptions for 2023. It is raising $27.4 million to...

voxmarkets.com
1
2
234
Load more